Dataset from Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial

The purpose of the TiME Trial is to determine whether dialysis facility implementation of a
minimum hemodialysis session duration of 4.25 hours (versus usual care) for patients with
end-stage renal disease initiating treatment with thrice weekly maintenance hemodialysis has
benefits on mortality, hospitalizations and health-related quality of life.

The trial also aims to demonstrate the capacity to conduct a large, pragmatic clinical trial
in partnership with two large dialysis provider organizations.